

# Myc Proto Oncogene Protein - Drugs In Development, 2021

<https://marketpublishers.com/r/M733EC4D4C54EN.html>

Date: July 2021

Pages: 69

Price: US\$ 3,500.00 (Single User License)

ID: M733EC4D4C54EN

## Abstracts

Myc Proto Oncogene Protein - Drugs In Development, 2021

### SUMMARY

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 23 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Myc Proto Oncogene Protein - Drugs In Development, 2021, outlays comprehensive information on the Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 8 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy

areas Oncology which include indications Solid Tumor, Hematological Tumor, Lymphoma, Breast Cancer, Unspecified Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Burkitt Lymphoma, Colon Cancer, Colorectal Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Leukemia, Lung Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)

The report reviews Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Myc Proto Oncogene Protein

(Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics and enlists all their major and minor projects

The report assesses Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Overview

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Companies Involved in Therapeutics Development

Anima Biotech Inc

Arvinas Inc

Biogen SpA

Escend Pharmaceuticals Inc

Gibson Oncology LLC

Kintor Pharmaceutical Ltd

Kronos Bio Inc

MecRx Pty Ltd

OncoViRx LLC

Origenis GmbH

Peptomyc SL

PYCTX Ltd

Recursion Pharmaceuticals Inc

Sapience Therapeutics Inc

SyntheX Inc

TheraMyc Ltd

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Drug Profiles

Amy-22 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
BGA-003 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Drugs to Inhibit MYC for Breast Cancer - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
ES-4000 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
GT-19077 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
NOV-1701 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
OMO-101 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
OMO-103 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
REC-0162977 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
REC-841 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress

Small Molecule to Target c-Myc for Multiple Myeloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Myc and Ubiquitin Protein Ligase for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit c-Myc for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit C-Myc for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit cMYC and PTEN for Unspecified Cancers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit cMyc for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MYC and NFKB for Lymphomas and Leukemias - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MYC and TOP1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MYC for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STX-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit C-Myc for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit cMyc for Hematological Tumor and Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Dormant Products

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Discontinued Products

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Product Development Milestones

Featured News & Press Releases

May 06, 2021: Peptomyc SL announces treatment of first patient with its lead compound OMO-103 in a phase I/II clinical trial

Mar 17, 2021: Omomyc, a drug developed in Vall d'Hebron, is coming to the clinical trial

Jul 30, 2020: VHIO and home-grown spin-off Peptomyc S.L receive further funding to bring Omomyc closer to the clinic

Jun 22, 2020: Pioneer Pharmaceuticals released the latest research results of c-Myc inhibitors at the AACR annual meeting

Apr 01, 2019: First published demonstration of the success of Myc inhibition by Omomyc mini-protein hits Science Translational Medicine and the news

Mar 26, 2019: Preclinical validation of new cancer inhibitor from EIT Health-supported Peptomyc

Mar 14, 2019: A new approach to drugging a difficult cancer target

Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer

Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer

Appendix



[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2021  
Number of Products under Development by Therapy Areas, 2021  
Number of Products under Development by Indication, 2021  
Number of Products under Development by Companies, 2021  
Products under Development by Companies, 2021  
Products under Development by Companies, 2021 (Contd..1)  
Number of Products under Investigation by Universities/Institutes, 2021  
Products under Investigation by Universities/Institutes, 2021  
Number of Products by Stage and Mechanism of Actions, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Pipeline by Anima Biotech Inc, 2021  
Pipeline by Arvinas Inc, 2021  
Pipeline by Biogen SpA, 2021  
Pipeline by Escend Pharmaceuticals Inc, 2021  
Pipeline by Gibson Oncology LLC, 2021  
Pipeline by Kintor Pharmaceutical Ltd, 2021  
Pipeline by Kronos Bio Inc, 2021  
Pipeline by MecRx Pty Ltd, 2021  
Pipeline by OncoViRx LLC, 2021  
Pipeline by Origenis GmbH, 2021  
Pipeline by Peptomyc SL, 2021  
Pipeline by PYCTX Ltd, 2021  
Pipeline by Recursion Pharmaceuticals Inc, 2021  
Pipeline by Sapience Therapeutics Inc, 2021  
Pipeline by SyntheX Inc, 2021  
Pipeline by TheraMyc Ltd, 2021  
Dormant Projects, 2021  
Discontinued Products, 2021

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

## I would like to order

Product name: Myc Proto Oncogene Protein - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/M733EC4D4C54EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M733EC4D4C54EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970